Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 23, 2026Thrombosis JournalOpen Access

Adverse factors associated with mortality among patients with immune-mediated thrombotic thrombocytopenic purpura in Taiwan: a single-institute cohort study

View Full Paper
Ask AI
Bookmark
Share

Authors

HLHsuan‐Yu LinChanghua Christian HospitalCLChing‐Yeh LinTaichung HospitalJLJen-Shiou LinChanghua Christian Hospital

Discussion

Loading...

Member takes

Overview

Cohort study identifies severe neurological impairment and high lactate dehydrogenase as major mortality predictors in immune-mediated thrombotic thrombocytopenic purpura, highlighting high-risk...

Key Points

  • Investigate the clinical characteristics, treatment outcomes, and mortality risk factors among patients diagnosed with immune-mediated thrombotic thrombocytopenic purpura.
  • Retrospectively analyzed 22 patients (14 male, 8 female; median age 61.5 years) with acute immune-mediated thrombotic thrombocytopenic purpura between 2012 and 2023 at a single institute in Taiwan.
  • Assessed clinical features, standard therapeutic plasma exchange and glucocorticoids, and measured ADAMTS13 activity and autoantibodies via FRET, ELISA, and Bethesda assays.
  • Initial clinical response was achieved in 17 of 22 patients (77.2%), while 5 patients (22.8%) were refractory to treatment and died.
  • Following plasma exchange cessation, 13 patients maintained clinical remission (8 with ADAMTS13 remission), though 4 had exacerbations and 3 experienced relapses.
  • Mortality was significantly associated with major neurological impairment (p = 0.005), serum lactate dehydrogenase over 5-fold normal (p = 0.039), and treatment refractoriness (p < 0.001).

Cite This Study

Lin et al. (2026) studied this question.

synapsesocial.com/papers/6a8aae007677a34114446a95https://doi.org/10.1186/s12959-026-00907-z
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Severe Immune-Mediated Thrombotic Thrombocytopenic Purpura With High-Titer ADAMTS13 Inhibitors: A Case Report2026
  2. 2Prognostic Relevance of Early Clinical and Laboratory Findings in Immune-Mediated Thrombotic Thrombocytopenic purpura2025
  3. 3Severe immune thrombotic thrombocytopenic purpura with neurologic involvement: a case report2026
  4. 4Features and Relapse/Refractory Disease Risk Factors of Patients with Acquired Thrombotic Thrombocytopenic Purpura in the Western Mediterranean Region of Turkey2024
  5. 5Unbiased plasma proteomics reveals hemolysis during ADAMTS13 relapse in patients with immune TTP.2026